Emerging innovative companies in the pharma/biotech field face earlier generic competition than ever before, including through USPTO post-grant challenges that are faster than typical litigation and have a higher rate of invalidating claims. It is vital to have a cohesive IP strategy that factors in key regulatory milestones and seeks varied claim scope to minimize risk of generic entry.

This panel will provide a roadmap for successfully protecting a new pharma/biotech product and flagging key decision points as it advances through Phase I, II and III clinical trials. Additionally, panelists will teach companies how to think critically about actions during drug development that may advance their strategic IP positions.

Ability Level: All

Session ID: 503579